ER
Publicaties op Oncologisch.com
Ten-year survival rates by PSA nadir in patiënten met metastatic hormone-sensitive prostate cancer: long-term surviva...
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year...
Pembrolizumab bij urotheelcarcinoom: KEYNOTE-045/052 gepoolde analyse